UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Biofutur, ISSN 0294-3506, 01/2017, Volume 36, Issue 384, p. 40
Journal Article
1996, Salisbury medical bulletin, Volume Number 87., 151
Book
3.
Full Text
BslA, the S‐layer adhesin of B. anthracis, is a virulence factor for anthrax pathogenesis
Molecular microbiology, ISSN 0950-382X, 01/2010, Volume 75, Issue 2, pp. 324 - 332
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Biological and medical sciences | Miscellaneous | Bacteriology | Virulence Factors - genetics | Bacillus anthracis - pathogenicity | Adhesins, Bacterial - genetics | Humans | Bacterial Toxins - toxicity | Immunoblotting | Virulence Factors - immunology | Anthrax Vaccines - immunology | Adhesins, Bacterial - toxicity | Anthrax - prevention & control | Bacterial Adhesion - physiology | Anthrax Vaccines - therapeutic use | Bacillus anthracis - genetics | Anthrax - pathology | Anthrax Vaccines - genetics | Virulence Factors - deficiency | Guinea Pigs | Anthrax - immunology | HeLa Cells - microbiology | Bacterial Toxins - metabolism | Animals | Bacterial Adhesion - genetics | Mutation | Adhesins, Bacterial - immunology | Anthrax - transmission | Proteins | Anthrax vaccine | Anthrax | Protein binding | Pathology | Bacteria | Molecular biology | Index Medicus
Journal Article
European journal of pharmaceutics and biopharmaceutics, ISSN 0939-6411, 06/2015, Volume 93, pp. 149 - 164
Compound 48/80 | Nanoparticles | Mucosal immunity | Nasal vaccination | Mast cell activator | Alginate | Anthrax protective antigen | Chitosan | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Adjuvants, Immunologic - administration & dosage | Humans | Anthrax Vaccines - administration & dosage | Anthrax Vaccines - immunology | Immunity, Mucosal - drug effects | p-Methoxy-N-methylphenethylamine - immunology | Anthrax - prevention & control | Time Factors | Surface Properties | Glucuronic Acid - administration & dosage | Nasal Mucosa - drug effects | Immunization | Antigens, Bacterial - chemistry | Anthrax - immunology | Bacterial Toxins - immunology | Chitosan - immunology | Technology, Pharmaceutical - methods | Biomarkers - blood | Hexuronic Acids - chemistry | Bacterial Toxins - chemistry | Particle Size | Anthrax - blood | Chitosan - chemistry | Bacterial Toxins - administration & dosage | RAW 264.7 Cells | Mice | Anthrax Vaccines - chemistry | T-Lymphocytes, Helper-Inducer - microbiology | Antigens, Bacterial - immunology | Hexuronic Acids - administration & dosage | Drug Carriers | Mast Cells - microbiology | Dose-Response Relationship, Drug | T-Lymphocytes, Helper-Inducer - drug effects | Adjuvants, Immunologic - chemistry | T-Lymphocytes, Helper-Inducer - immunology | Female | Glucuronic Acid - chemistry | p-Methoxy-N-methylphenethylamine - chemistry | Antibodies, Bacterial - blood | Nanomedicine | p-Methoxy-N-methylphenethylamine - administration & dosage | Mast Cells - immunology | Mice, Inbred C57BL | Chitosan - administration & dosage | Antigens, Bacterial - administration & dosage | Administration, Intranasal | Mast Cells - drug effects | Anthrax - microbiology | Chemistry, Pharmaceutical | Alginates - administration & dosage | Animals | Nasal Mucosa - immunology | Alginates - chemistry | Vaccines | Index Medicus
Journal Article
Emerging infectious diseases, ISSN 1080-6040, 2014, Volume 20, Issue 2
Bacillus anthracis - pathogenicity | Lactation | United States | Humans | Antibodies, Monoclonal - therapeutic use | Infant | Postpartum Period | Anthrax Vaccines - administration & dosage | Pregnancy Complications, Infectious - immunology | Anti-Bacterial Agents - therapeutic use | Antitoxins - therapeutic use | Anthrax - prevention & control | Anthrax - drug therapy | Pregnancy Complications, Infectious - prevention & control | Adult | Female | Fetus | Bacillus anthracis - drug effects | Pregnancy Complications, Infectious - microbiology | Anthrax - immunology | Bioterrorism | Centers for Disease Control and Prevention (U.S.) | Anthrax - microbiology | Pregnancy | Pregnancy Complications, Infectious - drug therapy | Bacillus anthracis - immunology | Practice Guidelines as Topic | Index Medicus | Bacillus anthracis | treatment | breast-feeding | Suggested citation for this article: Meaney-Delman D, Zotti ME, Creanga AA, Misegades LK, Wako E, Treadwell TA, et al | bacteria | postpartum period | pregnancy | antitoxins | dx.doi.org | anthrax | postexposure prophylaxis | vaccine | Online Report | antimicrobial drugs | 10.3201 | eid2002.130611 | antibacterial agents | lactation | PEP | antibiotics | women | vaccination | Workgroup on Anthrax in Pregnant and Postpartum Women. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis [Internet]. 2014 Feb [date cited]. http
Journal Article
Emerging infectious diseases, ISSN 1080-6040, 2014, Volume 20, Issue 2
Clinical Competence | Anthrax - immunology | Bacillus anthracis - pathogenicity | United States | Humans | Antibodies, Monoclonal - therapeutic use | Bioterrorism | Centers for Disease Control and Prevention (U.S.) | Anthrax - microbiology | Anthrax Vaccines - administration & dosage | Anti-Bacterial Agents - therapeutic use | Antitoxins - therapeutic use | Anthrax - prevention & control | Immunoglobulins, Intravenous - therapeutic use | Anthrax - drug therapy | Bacillus anthracis - immunology | Adult | Critical Care | Bacillus anthracis - drug effects | Disease Management | Practice Guidelines as Topic | Index Medicus | raxibacumab | Bacillus anthracis | treatment | bioterrorism and preparedness | Online Report | bacteria | Centers for Disease Control and Prevention | antitoxin | adults | anthrax | expert panel meeting | prevention
Journal Article
Vaccine, ISSN 0264-410X, 2016, Volume 34, Issue 18, pp. 2096 - 2105
Allergy and Immunology | BioThrax® (Anthrax Vaccine Adsorbed) | Vaccine | Post-exposure prophylaxis | Anthrax | CPG 7909 | BioThrax | Anthrax Vaccine Adsorbed | Immunology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Oligodeoxyribonucleotides - administration & dosage | Adjuvants, Immunologic - administration & dosage | Double-Blind Method | Humans | Middle Aged | Post-Exposure Prophylaxis - methods | Male | Anthrax Vaccines - administration & dosage | Young Adult | Anthrax - prevention & control | Adult | Female | Immunization Schedule | Anthrax Vaccines - therapeutic use | Antibodies, Bacterial - blood | Antibodies, Neutralizing - blood | Anthrax Vaccines - adverse effects | Anthrax vaccine | Vaccination | Safety and security measures | Urine | Antigens | Hispanic Americans | Infections | Blood pressure | Vaccines | Drug dosages | Investigations | Index Medicus | vaccine | anthrax | post-exposure prophylaxis
Journal Article
Annual review of microbiology, ISSN 0066-4227, 10/2015, Volume 69, Issue 1, pp. 185 - 208
anthrax toxins | edema factor | lethal factor | protective antigen | Anthrax toxins | Protective antigen | Edema factor | Lethal factor | Bacillus anthracis - pathogenicity | Anthrax - therapy | Humans | Bacterial Capsules - physiology | Anthrax - microbiology | Bacillus anthracis - physiology | Bacterial Toxins - metabolism | Animals | Spores, Bacterial - physiology | Bacillus anthracis - growth & development | Anthrax - veterinary | Bacillus anthracis - genetics | Antigens, Bacterial - metabolism | Anthrax | Host-bacteria relationships | Bacillus anthracis | Observations | Health aspects | Antigens | Signal transduction | Microbiology | Pathogenesis | Toxins | Cells | Index Medicus
Journal Article